Medacta Group SA Posts Strong Revenue Growth in H1 2025

Medacta Group SA reports substantial revenue growth of 19.8% in constant currency for the first half of 2025, with total revenue reaching Euro 344.1 million. The company noted significant expansion in all geographic regions, particularly in Asia Pacific and North America, which saw increases of 25.3% and 21.5% respectively.

Product lines showed impressive growth as well, with the Knee segment rising by 23.8% and Extremities increasing by an impressive 44.0% in constant currency. The recent acquisition of Parcus Medical also contributed to this growth, adding 1.2% to the Group's revenue. The acquisition expands Medacta’s presence in sports medicine.

Medacta has upgraded its revenue growth expectations for FY 2025 to between 16% and 18%, and set a target EBITDA margin of around 28%. The outlook for the mid-term has also been raised, with a projected compound annual growth rate of 10% to 14% in constant currency through 2027.